ObjectiveTo investigate the effectiveness of salivary-gland and oral-mucosa massage in alleviating xerostomia, which is an adverse effect of antipsychotics, in patients with schizophrenia and to investigate factors associated with its efficacy and clarify its indications. MethodsIn this randomized controlled trial, 47 patients with chronic schizophrenia were randomly divided into the intervention and control groups. The intervention group underwent salivary-gland and oral-mucosa massage and was followed up from baseline to week 8. The control group was assessed at baseline and after 8 weeks. ResultsOverall, 30 patients completed the study (15 in the intervention group and 15 in the control group). In the intervention group, the salivary flow rate stimulated by the chewing gum test significantly increased after 8 weeks. Furthermore, the use of first-generation antipsychotic (FGA) equivalents was significantly higher in patients whose salivary flow rate was unchanged after salivary gland oral-mucosal massage than in patients who showed improvement. Compared with the patients who used SGA alone, those who used second-generation antipsychotics (SGAs) and FGAs had less recognition of the tendency for salivary secretion to increase, and most of them used levomepromazine, an FGA with high muscarinic receptor affinity. ConclusionsSalivary-gland and oral-mucosa massage may promote salivation in patients with chronic schizophrenia. FGA intake inhibited the effects of the massage, and levomepromazine may have influenced this inhibition. Understanding the interactions between levomepromazine and salivary-gland and oral-mucosa massage can improve treatment strategies and patient care in chronic schizophrenia.
Read full abstract